Abstract |
FMS-related tyrosine kinase receptor 3 (FLT3) is a class III receptor tyrosine kinase that holds considerable promise as a therapeutic target in hematologic malignancies. Current efforts directed toward the development of small-molecule tyrosine kinase inhibitors of FLT3 may be limited by off-target toxicities and the development of drug resistance. Target-specific antibodies could overcome these hurdles and provide additional mechanisms to enhance the antitumor efficacy of FLT3 inhibitors. IMC-EB10 is a novel antibody directed against FLT3. The binding of IMC-EB10 to FLT3 results in antiproliferative effects in vitro and in mouse models engrafted with human leukemia cells that harbor wild-type or constitutively activated FLT3. Future clinical trials will test these notions formally and will identify the most appropriate opportunities for this member of a new generation of antileukemic therapies.
|
Authors | Hagop Youssoufian, Eric K Rowinsky, James Tonra, Yiwen Li |
Journal | Cancer
(Cancer)
Vol. 116
Issue 4 Suppl
Pg. 1013-7
(Feb 15 2010)
ISSN: 0008-543X [Print] United States |
PMID | 20127944
(Publication Type: Journal Article)
|
Copyright | (c) 2010 American Cancer Society. |
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- IMC-EB10
- Immunoglobulin G
- Protein Kinase Inhibitors
- fms-Like Tyrosine Kinase 3
|
Topics |
- Animals
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Drug Delivery Systems
- Humans
- Immunoglobulin G
(therapeutic use)
- Leukemia
(drug therapy)
- Mice
- Mutation
- Protein Kinase Inhibitors
(therapeutic use)
- fms-Like Tyrosine Kinase 3
(antagonists & inhibitors, genetics, immunology)
|